Bryce and Ren are joined by Rikki Bannan, who's Executive Director and Portfolio Manager at IFM Investors. She'll be speaking at the Hearts & Minds conference on the 17 November, but that stock is under lock and key, so we've asked her to bring two of her other picks to talk about today - 2 small caps: Propel Funeral Services (ASX: PFP) and Clarity Pharmaceuticals (ASX: CU6).

If you want to attend the Hearts and Minds conference, we've a promo code for online tickets. Use promo code: EQUITYMATES2023 and get a 20% discount available exclusively for the Equity Mates Community.

*

Ticket price for Equity Mates Community: $400

*

Ticket Link: https://hubs.la/Q025W_5y0

Discount Code: EQUITYMATES2023

If you want to go beyond the podcast and learn more, check out our accompanying email.

*****

In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing Podcast acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander people today.

*****

Equity Mates Investing Podcast is a product of Equity Mates Media.

This podcast is intended for education and entertainment purposes. Any advice is general advice only, and has not taken into account your personal financial circumstances, needs or objectives.

Before acting on general advice, you should consider if it is relevant to your needs and read the relevant Product Disclosure Statement. And if you are unsure, please speak to a financial professional.

Equity Mates Media operates under Australian Financial Services Licence 540697.

Equity Mates is part of the Acast Creator Network.

Hosted on Acast. See acast.com/privacy for more information.

Expert: Rikki Bannan - Two small caps: Propel Funeral Services (ASX: PFP) and Clarity Pharmaceuticals (ASX: CU6)

Equity Mates Investing Podcast

Expert: Rikki Bannan - Two small caps: Propel Funeral Services (ASX: PFP) and Clarity Pharmaceuticals (ASX: CU6)